Orexo Ab (publ)(OTC) ORXOY

Orexo AB (publ) is a specialty pharmaceutical company focused on developing and commercializing innovative pharmaceuticals and digital therapies. The company operates primarily in the United States, European Union, and the United Kingdom, addressing critical health issues such as opioid use disorder and pain management.

Products and Services

• Zubsolv tablets for opioid use disorder treatment
• Abstral for breakthrough pain in cancer patients
• Digital therapies including deprexis for depression management

Growth Outlook

• Recent collaboration with Abera Bioscience for nasal powder vaccines
• Development of OX124 and OX125 for opioid overdose rescue
• Expansion of digital therapy offerings to enhance patient care

Financial Highlights

• Recent quarterly revenue of 5 million SEK, showing potential for growth
• Cash and cash equivalents of 386 million SEK, providing operational stability
• Trailing twelve months (TTM) cash flow coverage ratio of 15.26, indicating strong liquidity

Orexo AB (publ) is positioned in the healthcare sector, specifically within pharmaceuticals, with a focus on addressing significant health challenges. The company’s product portfolio includes Zubsolv, which is pivotal in treating opioid use disorder, and Abstral, aimed at managing severe pain in cancer patients. Additionally, Orexo is advancing its digital therapy solutions, which are designed to support patients in managing conditions such as depression and alcohol use. The growth outlook for Orexo appears promising, bolstered by strategic collaborations and ongoing product development. The partnership with Abera Bioscience to create nasal powder vaccines highlights the company's commitment to innovation. Furthermore, the development of OX124 and OX125 for opioid overdose rescue reflects Orexo's dedication to addressing urgent healthcare needs. Financially, Orexo has demonstrated resilience, with a recent quarterly revenue of 5 million SEK. The company maintains a robust cash position, with 386 million SEK in cash and cash equivalents, ensuring operational flexibility. The trailing twelve months cash flow coverage ratio of 15.26 underscores the company's strong liquidity, providing a solid foundation for future growth initiatives. Overall, Orexo AB (publ) presents a compelling opportunity for investors interested in the pharmaceutical sector, particularly in innovative solutions for pressing health issues.